A novel complex insertion–deletion mutation in ADAR1 gene in a Chinese family with dyschromatosis symmetrica hereditaria

of 0.20 J per treatment as tolerated. Topical therapy included pimecrolimus cream nightly and sodium sulfacetamide cleanser twice daily. After 13 treatments with PUVA, she reached a dose of 2.6 J per treatment with excellent repigmentation of the affected areas (Fig. 2). Three months after discontinuation of PUVA therapy, the patient had a mild recurrence of the hypopigmentation of the eyebrow area and topical PUVA was restarted twice weekly resulting in excellent repigmentation. PUVA therapy was slowly tapered and finally discontinued after 5 months. Two years later, she was doing well, with normal pigmentation of the previously affected areas. Despite adequate control of inflammation, post-inflammatory hypopigmentation from seborrheic dermatitis can be a vexing problem, particularly in patients with darker skin types. Current treatment strategies for post-inflammatory hypopigmentation include topical corticosteroids and immunomodulators, cosmetic cover-ups, topical or oral PUVA, narrow band ultraviolet B and excimer lasers. Topical PUVA therapy has been used for postinflammatory hypopigmentation because of pityriasis versicolor and pityriasis alba. However, to our knowledge, the use of topical PUVA specifically for post-inflammatory hypopigmentation secondary to seborrheic dermatitis has not been previously reported. Further, larger studies using topical PUVA should be performed to determine the true efficacy of this treatment modality.